Drug Sponsors

SAGE Therapeutics awarded NIH grant for Fragile X Syndrome

Thursday, August 1, 2013 10:30 AM

The NIH has granted SAGE Therapeutics, a neuroscience product-focused company creating novel medicines to treat central nervous system (CNS) disorders, an award potentially worth up to $10 million to support the company's development of a novel drug which could be used to treat anxiety and social deficits in patients with Fragile X Syndrome (FXS).

More... »

WIRB Copernicus Group

Actelion to acquire Ceptaris

Thursday, August 1, 2013 10:00 AM

San Francisco, Calif.-based pharmaceutical company Actelion will acquire Ceptaris Therapeutics, contingent upon certain closing conditions, including FDA approval of Ceptaris' product, VALCHLOR.

More... »

CRF Health eCOA webinar series

Cubist to acquire Optimer, Trius

Wednesday, July 31, 2013 11:43 AM

Cubist Pharmaceuticals has signed agreements to acquire both Optimer Pharmaceuticals and Trius Therapeutics. Both transactions have been approved by company boards of directors and are expected to close later this year, subject to stockholder approval.

More... »

Pfizer to create separate internal, global innovative and value businesses

Monday, July 29, 2013 03:00 PM

Pfizer has announced plans to internally separate its commercial operations into three business segments, two of which will include innovative business lines and a third to include the value business line. 

More... »

PSI expands South African clinical trial presence

Monday, July 29, 2013 01:29 PM

Switzerland-based CRO PSI has expanded into South Africa and will expand its access to all African countries from its base in Pretoria. PSI's experience in South Africa includes oncology, CNS, urology and diabetes.

More... »

Perrigo to acquire Elan for $8.6 billion

Monday, July 29, 2013 11:02 AM

Allegan, Mich.-based Perrigo, a global provider of healthcare products and Elan, a Dublin-based biotechnology company, have entered into a definitive agreement under which Elan will be acquired by a new holding company incorporated in Ireland (“New Perrigo”).

More... »

Recordati acquires Tunisian pharmaceutical Opalia Pharma

Friday, July 26, 2013 03:06 PM

International pharmaceutical group Recordati has acquired Opalia Pharma, a Tunisian pharmaceutical company. The transaction is valued at $48 million, paid in cash, and is subject to prior approval by Tunisian authorities. Opalia Pharma markets dermatology, gastrointestinal and respiratory therapeutic products in a cGMP certified facility specialized in liquid and semi-solid forms.

More... »

Teva, Lonza discontinue biosmilar venture

Friday, July 26, 2013 09:30 AM

Teva Pharmaceutical Industries of Jerusalem and Lonza Group, based in Switzerland, have decided to discontinue their joint venture for the development, manufacturing and marketing of biosimilars. The companies said ending the collaboration, which began in 2009, will enable both to better advance their own strategies and efforts.

More... »

Vivus board appoints new chairman, CEO

Wednesday, July 24, 2013 03:00 PM

Biopharmaceutical company Vivus’ board of directors has appointed Michael Astrue chairman and Anthony Zook chief executive officer.

More... »

Quest PharmaTech, AD Biotech form joint cancer venture

Wednesday, July 24, 2013 02:15 PM

Quest PharmaTech, a pharmaceutical company developing and commercializing cancer treatment products, has entered into a relationship with Korean-based AD Biotech to share research and technology development resources to co-develop technologies of both companies.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs